IMV Inc. (IMV)


-0.01 (-4.79%)
Symbol IMV
Price $0.2464
Beta 1.512
Volume Avg. 0.09M
Market Cap 20.296M
Shares () -
52 Week Range 0.24-1.53
1y Target Est -
DCF Unlevered IMV DCF ->
DCF Levered IMV LDCF ->
ROE -560.29% Strong Sell
ROA -127.35% Strong Sell
Operating Margin -
Debt / Equity -611.04% Strong Sell
P/E -0.48 Neutral
P/B -3.21 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest IMV news

Mr. Frederic Ors
NASDAQ Capital Market

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.